Search results
Taysha Gene Therapies (NASDAQ:TSHA) Receives “Buy” Rating from Needham & Company LLC
ETF DAILY NEWS· 5 days agoNeedham & Company LLC reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports ...
Flexibility of alternative trial designs crucial for cell and gene therapy research
Clinical Trials Arena via Yahoo Finance· 4 days agoInnovative trial designs, like single group assignment, adaptive, basket, umbrella and platform...
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 1 day agoWith a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is...
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
Zacks via Yahoo Finance· 9 hours agoThis was due to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline...
Madison-based life science company Mirus Bio to be acquired for $600 million
Small Business Times· 7 hours agoMadison-based Mirus Bio, a manufacturer of transfection regents used in gene therapies, has entered...
Innovative Thinking Could Make New Sickle Cell Treatments More Accessible
Scientific American· 1 day agoLast fall, to great fanfare, US regulators approved two gene therapies for sickle cell disease, and...
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
Zacks· 19 hours agoThis was due to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. In May 2023, the FDA approved Vyjuvek, the first ever redosable gene
New Gene Therapy Approach Breaks Barriers for Treating Neurological Disorders
Gadgets 360· 2 days agoResearchers at the Broad Institute of MIT and Harvard have developed a promising gene delivery...
UTSW study sheds light on rare form of autism | Newswise
Newswise· 19 hours agoMay 23, 2024 – A new study focused on the gene tied to a rare form of autism spectrum disorder (ASD)...
U.S. BIOSECURE Act: Key considerations for global cell, tissue, and gene therapy stakeholders | JD...
JD Supra· 2 days agoWhile the landscape continues to evolve rapidly, there are steps that life sciences companies – particularly cell, tissue, and gene therapy (CTGT) and other ...